Biomeditsina va amaliyot jurnali, 2022 №3

Subject of the article

MODERN CONCEPTS ON THE STATE OF THE ISSUE OF CARDIO-VASCULAR COMPLICATIONS IN CUSHING'S SYNDROME (386-400)

Authors

XALIMOVA Zamira Yusupovna JABBOROVA Gavxar Muzravjonovna XOLOVA Dilorom Sharipovna

Institution

Respublika ixtisoslashtirilgan ilmiy-amaliy tibbiy endokrinologiya markazi

Abstract

Ushbu maqolada mualliflar so'nggi 5-10 yil ichida Kushing sindromida (КS) yurak-qon tomir muammolari bo'yicha adabiyotlarni tahlil qilish natijalarini taqdim etadilar. Mualliflarning xulosasiga ko'ra, KS ko'p qirrali kasallik bo'lib, uning turli jihatlari butun dunyodagi etakchi olimlarning e'tiborini tortadi. Ko'rib chiqilgan KS aspektlari neyroendokrinologiyaning dolzarb muammolaridir. Kasallikning etiologiyasi, patogenezi, klinik belgilari, erta diagnostika, davolash va uning asoratlari masalalarini muhokama qilish hali ham davom etmoqda va KSning yurak-qon tomir asoratlaridan o'lim xavfini prognozlashni rivojlantirish talab darajasida qolmoqda. Ushbu muammolarni hal qilish neyroendokrinologlarga duch keladi va turli sohalardagi mutaxassislarni jalb qilishni talab qiladi

Key words

Kushing sindromi, yurak-qon tomir asoratlari, adabiyotlarni ko'rib chiqish

Literature

1. Giraldi F. P. et al. Circadian blood pressure profile in patients with active Cushing's disease and after long-term cure //Hormone and metabolic research. – 2007. – Т. 39. – №. 12. – С. 908-914. 2. Исидори А.М. и соавт. Гипертоническая болезнь синдрома Кушинга: споры патофизиологии и акцент на сердечно-сосудистые осложнения // Журнал гипертонии. – 2015. – Т. 33. – №. 1. – С. 44. 3. Белая Ж. Е. и др. Метаболические осложнения эндогенного гиперкортицизма. Выбор пациентов для скрининга //Ожирение и метаболизм. – 2013. – №. 1 (34). – С. 26-31. 4. Гончаров Н.П., Колесникова Г.С. //Кортикостероиды: метаболизм, механизм действия и клиническое применение. М., 2002;48-75. 5. Пивонелло Р. и др. Метаболический синдром и сердечно-сосудистый риск при синдроме Кушинга // Клиника эндокринологии и обмена веществ. – 2005. – Т. 34. – №. 2. – С. 327- 339. 6. Беленков Ю. Н. Ремоделирование левого желудочка: комплексный подход //Журнал сердечная недостаточность. – 2002. – Т. 3. – №. 4. – С. 161-163. 7. Pivonello R. et al. The metabolic syndrome and cardiovascular risk in Cushing's syndrome //Endocrinology and Metabolism Clinics. – 2005. – Т. 34. – №. 2. – С. 327-339. 8. Григорьев А. Ю. Нейрохирургическое лечение пациентов с болезнью Иценко—Кушинга и акромегалией //Международный эндокринологический журнал. – 2011. – №. 5 (37). – С. 121-129. 9. Beller G. A., Zaret B. L. Contributions of nuclear cardiology to diagnosis and prognosis of patients with coronary artery disease //Circulation. – 2000. – Т. 101. – №. 12. – С. 1465-1478. 10. Dhingra A. et al. Pattern of Lipid Abnormalities Among South Asian Indians With Cushing’s Syndrome and the Short Term Impact of Surgical Correction of Hypercortisolism //Hormone and Metabolic Research. – 2019. – Т. 51. – №. 05. – С. 309-314. 11. Bouabdallaoui N. et al. Growth differentiation factor‐15 is not modified by sacubitril/valsartan and is an independent marker of risk in patients with heart failure and reduced ejection fraction: the PARADIGM‐HF trial //European journal of heart failure. – 2018. – Т. 20. – №. 12. – С. 1701-1709. 12. Гончаров Н. П. и др. Стероидогенез в коре надпочечников и секреция надпочечниковых андрогенов при болезни и синдроме Иценко–Кушинга //Проблемы эндокринологии. – 2007. – Т. 53. – №. 1. – С. 26-30. 13. Лилли Л. С. Патофизиология заболеваний сердечно-сосудистой системы. – БИНОМ. Лаб. знаний, 2007. 14. Akaza I. et al. Endothelial dysfunction associated with hypercortisolism is reversible in Cushing’s syndrome //Endocrine journal. – 2009. – С. 0912090367-0912090367. 15. Суровикина М.С., Калинин А.П. и др. Кининовая система крови при болезни Иценко- Кушинга и гормонально-активных опухолях надпочечников. //Пособие для врачей, М., 2000;4-11. 16. 16.Халимова З.Ю., Наримова Г.Д. Синдром Кушинга, эпидемиология и проблемные вопросы // Журнал Теоретической и Клинической медицины, Ташкент, 2013. - Специальный выпуск. – С. 94 – 97. 17. 17.Халимова З.Ю., Наримова Г.Д., Алимухамедова Г.О. Особенности нарушений костного метаболизма при синдроме Кушинга // Российский Нейрохирургический Журнал имени проф. А.Л. Поленова. - Санкт-Петербург, 2014. – Специальный выпуск. – Том 6. – С. 392-394. 18. И.И. Дедова, Г.А. Мельниченко . Эндокринология : нац. рук. / под ред.. - //М.: ГЭОТАР- Медиа, 2016. - С. 778-784, 823-832. 19. Arkoumani M. et al. The clinical impact of growth differentiation factor-15 in heart disease: A 2019 update //Critical Reviews in Clinical Laboratory Sciences. – 2020. – Т. 57. – №. 2. – С. 114-125. 20. Bolland M. J. et al. Mortality and morbidity in Cushing’s syndrome in New Zealand //Clinical endocrinology. – 2011. – Т. 75. – №. 4. – С. 436-442. 21. Ceccato F., Boscaro M. Cushing’s syndrome: screening and diagnosis //High Blood Pressure & Cardiovascular Prevention. – 2016. – Т. 23. – №. 3. – С. 209-215. 22. Chandran D. S. et al. Decreased autonomic modulation of heart rate and altered cardiac sympathovagal balance in patients with Cushing's syndrome: role of endogenous hypercortisolism //Neuroendocrinology. – 2013. – Т. 97. – №. 4. – С. 309-317. 23. Champagnac D. et al. Association of cutaneous myxoma, recurrent cardiac myxoma and Cushing's syndrome (Carney's complex). Description of a case and review of the literature //Archives des Maladies du Coeur et des Vaisseaux. – 1990. – Т. 83. – №. 1. – С. 121-124. 24. Czaja M. et al. Interpreting myocardial perfusion scintigraphy using single-photon emission computed tomography. Part 1 //Kardiochirurgia i Torakochirurgia Polska= Polish Journal of Cardio-Thoracic Surgery. – 2017. – Т. 14. – №. 3. – С. 192. 25. Dewey M. et al. Clinical quantitative cardiac imaging for the assessment of myocardial ischaemia //Nature Reviews Cardiology. – 2020. – Т. 17. – №. 7. – С. 427-450. 26. EMA E. M. A. European Medicines Agency recommends suspension of marketing authorisations for oral ketoconazole. – 2013. 27. 27. Fallo Francesco , Famoso Giulia, Capizzi Dario, Sonino Nicoletta, et all..Coronary microvascular function in patients with Cushing's syndrome// Endocrine2013 Feb;43(1):206- 13. 28. Erlic Z. et al. Targeted metabolomics as a tool in discriminating endocrine from primary hypertension //The Journal of Clinical Endocrinology & Metabolism. – 2021. – Т. 106. – №. 4. – С. e1111-e1128. 29. Eitel I. et al. Growth-differentiation factor 15 as predictor of mortality in acute reperfused STelevation myocardial infarction: insights from cardiovascular magnetic resonance //Heart. – 2011. – Т. 97. – №. 8. – С. 632-640. 30. Feelders R. A. et al. MANAGEMENT OF ENDOCRINE DISEASE: The burden of Cushing's disease: clinical and health-related quality of life aspects //European journal of endocrinology. – 2012. – Т. 167. – №. 3. – С. 311-326. 31. Fassnacht M. et al. Management of adrenal incidentalomas: European society of endocrinology clinical practice guideline in collaboration with the European network for the study of adrenal tumors //European journal of endocrinology. – 2016. – Т. 175. – №. 2. – С. G1-G34. 32. Findling J. W., Raff H. DIAGNOSIS OF ENDOCRINE DISEASE: Differentiation of pathologic/neoplastic hypercortisolism (Cushing's syndrome) from physiologic/non-neoplastic hypercortisolism (formerly known as pseudo-Cushing's syndrome) //European Journal of Endocrinology. – 2017. – Т. 176. – №. 5. – С. R205-R216. 33. O’Shaughnessy E. et al. FDA Public Workshop Summary—Coccidioidomycosis (Valley Fever): Considerations for Development of Antifungal Drugs //Clinical Infectious Diseases. – 2021. 34. Foley P. W. X. et al. Growth differentiation factor-15 predicts mortality and morbidity after cardiac resynchronization therapy //European heart journal. – 2009. – Т. 30. – №. 22. – С. 2749- 2757. 35. Fuertes M. et al. New insights in cushing disease treatment with focus on a derivative of vitamin A //Frontiers in Endocrinology. – 2018. – Т. 9. – С. 262. 36. Gizatulina T. P. et al. The association of growth differentiation factor 15 (GDF-15) level with extent of left atrial fibrosis in patients with nonvalvular atrial fibrillation //Kardiologiia. – 2020. – Т. 60. – №. 9. – С. 22-29. 37. Mancini T. et al. High cardiovascular risk in patients with Cushing's syndrome according to 1999 WHO/ISH guidelines //Clinical endocrinology. – 2004. – Т. 61. – №. 6. – С. 768-777. 38. Graversen D. et al. Mortality in Cushing's syndrome: a systematic review and meta-analysis //European Journal of Internal Medicine. – 2012. – Т. 23. – №. 3. – С. 278-282. 39. 39.Iwasaki Hiroaki . Reversible alterations in cardiac morphology and functions in a patient with Cushing's syndrome //Endocrinol Diabetes Metab Case Rep. 2014;2014:140038. 40. 40. Goh G. et al. Recurrent activating mutation in PRKACA in cortisol-producing adrenal tumors //Nature genetics. – 2014. – Т. 46. – №. 6. – С. 613-617. 41. 41. Tsuda K. et al. Electrocardiographic abnormalities in patients with Cushing's syndrome //Japanese heart journal. – 1995. – Т. 36. – №. 3. – С. 333-339. 42. 42. Raff H., Carroll T. Cushing's syndrome: from physiological principles to diagnosis and clinical care //The Journal of physiology. – 2015. – Т. 593. – №. 3. – С. 493-506. 43. Hinojosa-Amaya J. M., Cuevas-Ramos D., Fleseriu M. Medical management of Cushing’s syndrome: current and emerging treatments //Drugs. – 2019. – Т. 79. – №. 9. – С. 935-956. 44. 44.Hiroshi Nisioka, Sedzo Yamada. Cushing disease //J Clin Med. 2019 nov; 8 (11): 1951. Printed online, 12 november 2019 г. 45. Hopkins R. L., Leinung M. C. Exogenous Cushing's syndrome and glucocorticoid withdrawal //Endocrinology and Metabolism Clinics. – 2005. – Т. 34. – №. 2. – С. 371-384. 46. Hou G., Jiang Y., Cheng X. The Detection of Cardiac Adrenocorticotropic Hormone-Secreting Neuroendocrine Tumor With the Help of 68Ga-DOTATATE PET/CT //Clinical Nuclear Medicine. – 2020. – Т. 45. – №. 2. – С. 136-138. 47. Javanmard Pedram , Duan Daisy , Eliza B Geer .Mortality in Patients with Endogenous Cushing's Syndrome.// Endocrinol Metab Clin North Am2018 Jun;47(2):313-333. 48. 48.Jennifer E Ho , Anubha Mahajan, Ming-Huei Chen, Martin G Larson, Clinical and genetic correlates of growth differentiation factor 15 in the community// Clin Chem. 2012 Nov;58(11):1582-91. 49. Yau H. et al. Octreotide long-acting repeatable in the treatment of neuroendocrine tumors: patient selection and perspectives //Biologics: Targets & Therapy. – 2017. – Т. 11. – С. 115.